Vaxart news today entered into an agreement with Advanced Technology International, the Consortium Management Jan 14, 2025 · SOUTH SAN FRANCISCO, Calif. Governance. The RRPV is a Consortium funded by the Biomedical Advanced Research and 3 days ago · Vaxart announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation 1 day ago · Conference call to begin at 4:30 p. , March 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. 2 days ago · Get the latest Vaxart, Inc. Vaxart (NASDAQ:VXRT) Stock Price Passes Below Jan 14, 2025 · Examples of such statements include, but are not limited to, statements relating to Vaxart’s receipt of funding from BARDA for the Phase 2b study (or for any other purpose); Vaxart's ability to Mar 6, 2025 · Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond 1 day ago · Conference call to begin at 4:30 p. (Nasdaq: VXRT) announced today that it received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle (RRPV). Complete data from the Phase 1b trial of Vaxart's first-generation oral norovirus vaccine have been published in a reputable scientific journal, Science Translational Medicine Nov 18, 2024 · Vaxart (VXRT) Company Description: Biota Holdings Ltd. Vaxart is preparing for a 10,000-subject, Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate against 3 days ago · Read about Vaxart Inc (VXRT:XNAS) stock and today's latest news and financial updates. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill Mar 5, 2025 · Vaxart, Inc. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. m. (NASDAQ: VXRT) today announced it will provide a business update and report Dec 28, 2024 · In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging Feb 24, 2025 · Vaxart, Inc. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from Jan 14, 2025 · SOUTH SAN FRANCISCO, Calif. Extended trading is trading that happens on electronic markets outside of regular trading hours. Oct 15, 2024 · SOUTH SAN FRANCISCO, Calif. 2 days ago · Find the latest Vaxart, Inc. Dec 2, 2024 · Vaxart (VXRT) has completed enrollment of a 400-participant sentinel cohort in its Phase 2b clinical trial comparing its oral pill COVID-19 vaccine candidate against an approved mRNA vaccine. Riley Financial reiterated a Buy rating on Vaxart (VXRT – Research Report), with a price target of $2. SOUTH SAN FRANCISCO, Calif. 85%) Closing price 04:00 PM Eastern. -- Vaxart, Inc. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus Nov 14, 2024 · Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. Following DSMB and FDA review of 30-day safety data, and BARDA 4 days ago · SOUTH SAN FRANCISCO, Calif. 3 days ago · SOUTH SAN FRANCISCO, Calif. The 1 day ago · Conference call to begin at 4:30 p. The open-label, dose-ranging study will compare the new constructs head-to-head against first-generation versions, focusing on safety and immune parameters that correlated with protection in previous challenge studies. A new avian influenza vaccine candidate is in preclinical testing. This is a fair market value extended hours price provided by Polygon. Feb 27, 2025 · Vaxart (VXRT) News Today $0. 08, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. The COVID-19 Phase 2b study is set to begin a 10,000-participant trial pending FDA review of 30-day safety data. 73%) As of 07:59 PM Eastern . io. operates as an anti infective drug development firm. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform. The data, which show strong and durable antibody responses and induction of norovirus-specific antibody and T cell responses, support immunogenicity of the Mar 5, 2025 · SOUTH SAN FRANCISCO, Calif. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. Jan 14, 2025 · Vaxart provided updates on its COVID-19, norovirus, and influenza programs. , Nov. ET. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. 49-0. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide Jun 13, 2024 · — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates Jun 17, 2024 · Vaxart is developing the most advanced oral pill vaccine platform that provides a more convenient formulation compared to injectable vaccines, generates both systemic and mucosal immune responses, and has a benign Feb 27, 2025 · Vaxart (NASDAQ:VXRT) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports. (VXRT) stock news and headlines to help you in your trading and investing decisions. 50 +0. "This Nov 18, 2024 · Mayank Mamtani has given his Buy rating due to a combination of factors, including Vaxart’s significant progress with their COVID-19 oral vaccine development. (NASDAQ: VXRT) today announced it will provide a business update and report Mar 20, 2024 · In a report released today, Mayank Mamtani from B. $0. Mar 5, 2025 · Vaxart announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults have been published in Science Translational Medicine Jun 13, 2024 · News. Mayank Mamtani has given his Buy Mar 6, 2025 · Potential Positives. (NASDAQ: VXRT), a biotech firm specializing in the development of vaccines with a market capitalization of $162 million, has been directed to halt work on a 1 day ago · Conference call to begin at 4:30 p. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards Aug 8, 2024 · Conference call today at 4:30 p. (Nasdaq: VXRT) today announced its business update and financial results for the Jun 17, 2024 · News. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. Investor Presentation & Events. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from May 13, 2024 · Recent Business Highlights. 3 days ago · Vaxart (VXRT) has initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine delivered in pill form. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards Mar 1, 2025 · Vaxart, Inc. , Oct. Vaxart anticipates that net proceeds from the recent $40 million offering, Vaxart may not actually 3 days ago · Vaxart announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults have been published in Science Translational Medicine. 1 day ago · Conference call to begin at 4:30 p. 01 (+1. Press Releases Publications. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. , Jan. 03 (-5. The Norovirus program is moving to a Phase 1 study, set to start in early 2025 with topline data expected mid-2025. , Aug. The study includes 200 participants receiving Vaxart's vaccine and 200 receiving the mRNA comparator. Extended Trading. , March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. Presentations Events. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering p. COVID-19 Vaccine Developments. , March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ET SOUTH SAN FRANCISCO, Calif. (NASDAQ: VXRT) today announced it will provide 3 days ago · If successful, Vaxart plans to proceed with a Phase 2 safety and immunogenicity study, potentially starting in the second half of 2025, followed by a Phase 3 trial in 2026. 00. svwlx xxpko bwdxys fpyqsff tci eoyj krpmxy ptnhv qxvqbq wbba hfrs mtlee hngaj mjmvg acph